471 filings
Page 4 of 24
6-K
n4i5e7t5w zwq106
6 Mar 23
Vesting of awards under the Long Term Incentive Plan
6:01am
6-K
i0sjjq7d qvmilm8sx
28 Feb 23
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
6:09am
6-K
i16 i2p84hba
27 Feb 23
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
6:29am
SC 13G/A
ue5yb554mht3qw480
13 Feb 23
HUTCHMED (China) / Capital International Investors ownership change
3:54pm
6-K
60su vvwvdvx
31 Jan 23
HUTCHMED to Announce 2022 Final Results
6:03am
6-K
xs5vatg7bo
23 Jan 23
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
6:39am
6-K
avii1n8qc8j
18 Jan 23
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
9:13pm
6-K
skhu12z
3 Jan 23
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
6:01am
6-K
ns52cpvl9rm
30 Dec 22
Current report (foreign)
6:05am
6-K
xcxpk6wxg1jvj8
19 Dec 22
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
6:01am
6-K
ug357yljx0eg0n7nkx2
15 Nov 22
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
6:03am
6-K
njvv28
14 Nov 22
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
6:14am
6-K
ex3ic pv524x
27 Oct 22
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
7:38am
6-K
xkdo779w4u
21 Oct 22
Vesting of awards under the Long Term Incentive Plan
6:09am
6-K
5slld nddq1il
11 Oct 22
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
6:49am
6-K
8e1u0e7ckp8l2v1
30 Sep 22
Current report (foreign)
6:02am
6-K
929qfn3cuha177
14 Sep 22
Grant of Share Options under Share Option Scheme and Awards under
6:17am
6-K
sw4qgqm339
8 Sep 22
Current report (foreign)
6:12am
6-K
shb9m pb3buy
23 Aug 22
HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022
6:23am